IOVA — IOVANCE BIOTHERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1425205 ·
Last close
$7.53
Market Cap
$3.48B
52W High
$15.37
52W Low
$2.08
ADV30
14,226,309
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 99,313,000 | 55,718,000 | -51,905,000 | -47,315,000 | 915,531,000 | 110,768,000 | 179,486,000 |
| Mar 2026 | 71,430,000 | 28,932,000 | -81,043,000 | -79,045,000 | 925,665,000 | 196,508,000 | 203,911,000 |
| Dec 2025 | 86,771,000 | 43,660,000 | -73,460,000 | -71,904,000 | 913,170,000 | 163,078,000 | 214,587,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-264,182,000
Investing CF
$-44,869,000
Financing CF
$287,851,000
CapEx
$-32,213,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.53
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,901,890,000
Inventory
$55,590,000
Receivables
$81,758,000
ST Investments
$116,935,000
EBIT TTM
$-296,166,000
Pretax Income TTM
$-293,776,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$378,983,008
EBITDA
$-192,107,008
Free Cash Flow
$-187,794,752
Enterprise Value
$3,390,221,312
Total Cash
$297,673,984
Total Debt
$46,003,000
Shares Out
462,655,151
Trailing EPS
$-0.49
Book Value
$1.62
ROE
-40.4%
ROA
-20.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 263,502,000 | -398,213,000 | -390,978,000 | 913,170,000 | 214,587,000 | 698,583,000 | -302,408,000 |
| Dec 2024 | 164,070,000 | -395,278,000 | -372,177,000 | 910,426,000 | 200,021,000 | 710,405,000 | -352,977,000 |
| Dec 2023 | 1,189,000 | -460,559,000 | -444,037,000 | 780,351,000 | 195,738,000 | 584,613,000 | -361,820,000 |
| Dec 2022 | 0 | -398,878,000 | -395,893,000 | 663,982,000 | 164,344,000 | 499,638,000 | -292,757,000 |
TTM Snapshot
Revenues TTM
$324,969,000
NetIncome TTM
$-289,517,000
OpCashFlow TTM
—
Assets (Latest)
$915,531,000
Forward EPS
$-0.17
Max Pain — expiry 2026-12-18
max pain strike: $7.50 · spot: $7.48 · call oi: 17,445 · put oi: 8,563
Expected Move to 2026-12-18:
±$1.45
(19.39%) —
implied range
$6.03 –
$8.93
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | $3.64B | $16.47 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.86B | $78.20 | — |
| CRSP | CRISPR Therapeutics AG | $3.89B | $40.15 | — |
| ADMA | ADMA BIOLOGICS, INC. | $3.02B | $13.63 | — |
| VCEL | Vericel Corp | $2.95B | $57.88 | — |
News headlines (Yahoo Finance, 1h cache)
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
2026-11-16 15:14 · Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
2026-11-12 21:05 · Yahoo
Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More
2026-11-09 08:33 · Yahoo
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery
2026-11-07 06:13 · Yahoo
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
2026-11-06 12:31 · Yahoo
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...
2026-11-06 11:10 · Yahoo
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
2026-11-05 22:16 · Yahoo
Iovance (IOVA) Q3 2026 Earnings Call Transcript
2026-11-05 21:34 · Yahoo
Iovance Biotherapeutics Q3 Earnings Call Highlights
2026-11-05 21:14 · Yahoo
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.